medrogestone and Uterine-Neoplasms

Topics: Adult; Female; Gestrinone; Gonadotropin-Releasing Hormone; Humans; Leiomyoma; Medrogestone; Menopause; Uterine Neoplasms

Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Genital Neoplasms, Female; Humans; Medrogestone; Middle Aged; Neoplasm Metastasis; Ovarian Neoplasms; Parity; Pregnadienes; Progesterone; Progestins; Recurrence; Sarcoma; Uterine Cervical Neoplasms; Uterine Neoplasms

Vaginal sonography of the endometrium is a new method of controlling the substitution therapy with oestrogen and progesterone during the postmenopausal period. The advantages of transvaginal ultrasonic diagnosis are that the uterus can be seen from the fornix vaginae, that it is situated at close range, and that the examination can be conducted whether the bladder is filled or not. The differences in thickness and structure of the endometrium, and the limitation to the surrounding myometrium, enable sonographic detection of most of the changes of the endometrium during the postmenopausal period. In our first group of patients, we found an endometrial carcinoma in 2 out of the 60 women with postmenopausal metrorrhagia. The findings were confirmed histologically. Women who have regular bleedings while undergoing hormone therapy during the postmenopausal period, show signs of proliferation in the endometrium under oestrogen therapy and signs of secretion under progesterone therapy.

Topics: Climacteric; Endometrial Hyperplasia; Endometrium; Estrogens, Conjugated (USP); Female; Humans; Medrogestone; Metrorrhagia; Middle Aged; Ultrasonography; Uterine Neoplasms

Vaginal sonography of the endometrium is a new method of monitoring the effects of progestogen replacement therapy during the post-menopausal period. The advantages of transvaginal ultrasonic diagnosis are that the uterus can be seen from the fornix vaginae (that is from close range) and that the examination can be carried out whether the bladder is full or not. The differences in the thickness and structure of the endometrium, and the boundary with the surrounding myometrium, enable most of the endometrial changes that occur during the post-menopausal period to be detected sonographically. In the first group of patients we investigated, endometrial carcinoma was detected in 2 out of 60 women suffering from post-menopausal metrorrhagia, the findings subsequently being confirmed histologically. It was observed that post-menopausal women who have regular bleeding during post-menopausal hormone therapy show signs of endometrial proliferation during oestrogen therapy and of secretion during progestogen therapy.

Topics: Cell Division; Drug Therapy, Combination; Endometrium; Estrogens, Conjugated (USP); Female; Humans; Medrogestone; Menopause; Middle Aged; Pregnadienes; Ultrasonography; Uterine Neoplasms

Progestational agents induced an objective response in 11.2% of 155 patients with advanced primary or recurrent endometrial carcinoma. Response rates decreased with decreasing tumor differentiation from 40% with Broders grade 1 lesions to 17.5, 2.4, and 0%, respectively, with grades 2, 3, and 4. 17 alpha-Hydroxyprogesterone caproate (Delalutin), 6,17 alpha-dimethyl-6-dehydroprogesterone (Colprone), and 6-methyl-6-dehydroprogesterone acetate (Megace) were the progestogens used; there was no significant advantage for any one agent. Overall, survival after initiation of hormone therapy was 40% at one year, 19% at two years, and 8% at five years. Survival was highly dependent on the degree of tissue differentiation (P less than .001) and was influenced significantly by the estimated tumor volume at the start of therapy (P less than .01) and by the time interval from primary treatment to the beginning of hormone therapy (P less than .01).

Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Medrogestone; Megestrol; Neoplasm Recurrence, Local; Progesterone Congeners; Prognosis; Time Factors; Uterine Neoplasms

Six human endometrial cancers in different clinical stages were xenotransplanted into thymusaplastic nude mice. Estrogen and progesterone receptors in the tumor tissue were determined in each case. Two carcinomas with both estrogen and progesterone receptors showed a better clinical course and grew more slowly in nude mice than the four carcinomas with no receptors at all. Treatment with the antiestrogen Tamoxifen in the carcinoma with positive estrogen receptors showed a significant growth retardation compared with the control group. Estrogen treatment gave accelerated growth, whereas gestagen treatment showed no significant effect. The progesterone receptor content of the receptor-positive tumor tissue might have been too small. None of the four receptor-negative carcinomas showed any influence of tumor growth during endocrine therapy. The results demonstrate the importance of receptor determination as a prognostic sign and, further, allow the endocrine therapy of endometrial carcinomas to be complemented with Tamoxifen in estrogen-receptor-positive tumor tissue.

Topics: Aged; Animals; Estradiol; Female; Gestonorone Caproate; Humans; Male; Medrogestone; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Receptors, Drug; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Uterine Neoplasms

Topics: Aged; Female; Humans; Life Expectancy; Medrogestone; Medroxyprogesterone; Middle Aged; Pregnadienes; Prognosis; Uterine Neoplasms

Topics: Female; Humans; Hydroxyprogesterones; Medrogestone; Medroxyprogesterone; Megestrol; Progesterone; Progestins; Uterine Neoplasms

Since 1963 there have been 266 patients with cancer of the uterine fundus at the Medical University of South Carolina. Progestational agents were used to treat 54 but 10 received the drugs for less than 1 month. This report relates to the remaining 44. 34 were treated with Depo-Provera (medroxyprogesterone acetate), 9 with Colprone (megestrone acetate), and 1 with Megace (megestrol acetate). Of the 34 patients treated with Depo-Provera 13 showed regression of the tumor; 3 of the 9 treated with Colprone showed regression. In an additional 11 (25%) of cases growth of the tumors was arrested. 7 of these were later found to have abdominal metastases; however, 3 were free of symptoms for over 43 months. A patient on Depo-Provera with lung metastases had recurrence after 62 months when treatment was reduced to every other week but when Colprone was then given, regression again occurred and has continued for almost 10 years. Another patient not responding to Depo-Provera did respond to Colprone. Average duration of regression was 27.7 months, of survival 31.1 months. Arrest of growth was 25 months in some; survival averaged 23.4 months. (The 1 Megace case was in this group.)y Those having progression of tumors lived an average of 9 months with the longest survival 24 months. Of the responders 8 lived from 44 to 111 months and 5 remain alive, 4 now showing no evidence of the cancer. Tumors with well-differentiated, slow-growing lesions were most likely to respond. Site of recurrence did not seem to influence the response. No contraindications were found to use of progestational agents in this type of cancer. Local reactions to the injections were few. Subjective response was frequent even though progression was taking place.

Topics: Adenocarcinoma; Administration, Oral; Endometrium; Female; Humans; Injections, Intramuscular; Medrogestone; Medroxyprogesterone; Megestrol; Neoplasm Metastasis; Neoplasm Recurrence, Local; Progestins; Uterine Neoplasms